Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

8.84 (USD) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q4
Revenue 73.464.17974.14166.86568.91479.025204.713191.263242.732244.293228.444204.81217.775148.21198.35387.85946.90550.98135.96
Cost of Revenue 45.1445.20435.70836.68643.27333.67653.25338.17637.49640.03239.13832.04737.51330.36823.39519.7621.19715.29717.83
Gross Profit 28.2618.97538.43330.17925.64145.349151.46153.087205.236204.261189.306172.763180.262117.84374.95868.09925.70835.68418.13
Gross Profit Ratio 0.3850.2960.5180.4510.3720.5740.740.80.8460.8360.8290.8440.8280.7950.7620.7750.5480.70.504
Reseach & Development Expenses 5.2845.0324.5944.3474.1944.1455.0115.3894.2743.6959.1841.951.9322.1642.0921.8681.63.7440.979
General & Administrative Expenses 00000000000000000015.784
Selling & Marketing Expenses 0000000000000000000
SG&A 34.78931.19733.62638.86435.37738.67137.20330.79528.06133.225.58125.18924.08523.23741.62120.5115.98816.12615.784
Other Expenses -2.5620.1060.0490.066-1.620.1680.914-0.004-1.2750.0070.2010.078-0.0030.003-7.5980.0320.020.080.023
Operating Expenses 40.07336.22938.2243.21139.57142.81642.21436.18432.33536.89534.76527.13926.01725.40143.71322.37817.58819.8716.763
Operating Income -11.813-17.2540.213-15.417-11.614-2.161109.246116.903180.701167.366154.541156.873154.24592.44231.24545.7218.1234.8161.286
Operating Income Ratio -0.161-0.2690.003-0.231-0.169-0.0270.5340.6110.7440.6850.6760.7660.7080.6240.3180.520.1730.6830.036
Total Other Income Expenses Net -5.114-5.155655.973-3.3260.797-2.362-13.37-3.14-5.709-0.525-2.8314.573-0.0035.889-7.5980.0320.0219.082-0.058
Income Before Tax -16.927-22.409656.186-20.563-13.364-4.52395.876113.763174.992166.841144.689151.652145.7389.56114.84138.6640.67727.514-6.41
Income Before Tax Ratio -0.231-0.3498.851-0.308-0.194-0.0570.4680.5950.7210.6830.6330.740.6690.6040.1510.440.0140.54-0.178
Income Tax Expense -2.4350.271766.168-5.461-1.421-3.1758.44714.1118.27119.98117.57818.84211.38613.7090.369-0.359-0.7653.635-0.96
Net Income -7.585-12.078-105.959-6.462-6.541-1.34887.42999.653156.721146.8655.8354.27449.07523.24725.20938.950.20723.389-5.391
Net Income Ratio -0.103-0.188-1.429-0.097-0.095-0.0170.4270.5210.6460.6010.2440.2650.2250.1570.2560.4430.0040.459-0.15
EPS -0.056-0.091-0.8-0.049-0.05-0.010.660.760.610.580.420.460.440.240.60.440.0020.26-0.056
EPS Diluted -0.056-0.091-0.8-0.049-0.05-0.010.660.760.610.580.420.440.440.240.130.440.0020.26-0.056
EBITDA 2.734-3.50113.193-5.534-8.7598.746112.498116.899171.626174.755154.742145.702154.24292.44523.64752.42414.61522.668.025
EBITDA Ratio 0.037-0.0550.178-0.083-0.1270.1110.550.6110.7070.7150.6770.7110.7080.6240.240.5970.3120.4440.223